← Back to Clinical Trials
Recruiting NCT07244042

NCT07244042 Effects of Modified CIMT With and Without PNF

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07244042
Status Recruiting
Phase
Sponsor Riphah International University
Condition Pediatric Stroke
Study Type INTERVENTIONAL
Enrollment 20 participants
Start Date 2025-10-27
Primary Completion 2026-01-25

Eligibility & Interventions

Sex All sexes
Min Age 5 Years
Max Age 13 Years
Study Type INTERVENTIONAL
Interventions
Modified CIMTProprioceptive Neuromuscular Facilitation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 20 participants in total. It began in 2025-10-27 with a primary completion date of 2026-01-25.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This randomized clinical trial investigates the effects of modified CIMT with and without the addition of PNF techniques on upper extremity function in pediatric stroke patients, aiming to determine whether combining these approaches yields superior motor recovery.This study will be conducted as a randomized clinical trial over an intervention period of six-week. 20 pediatric stroke patients with upper extremity impairments will be randomly assigned to two groups: one receiving modified CIMT alone and the other receiving modified CIMT combined with PNF techniques. Pre- and post-intervention assessments will be conducted using standardized measures, such as Pediatric Motor Activity Log(PMAL) for upper extremity function, Modified Ashworth Scale(MAS) and Manual Ability Classification System(MACS). Muscle tone and physical activity status will also be evaluated. Data will be entered and analyzed in SPSS V-26.0 to compare improvements in motor function between the two groups, with statistical significance assessed to determine the efficacy of each intervention

Eligibility Criteria

Inclusion Criteria: * Paeds Patients with confirmed diagnosis of Stroke * Children between age 5 to 13 years * Modified Ashworth Scale spasticity level 1 and 2. * Patients having Manual Ability Classification System Score between 3 to 6. * GMFCS level 1 and 2 * Patient having in affected upper extremity at least 20◦ of active wrist extension starting from the full flexion, 10◦ of active extension or abduction in the thumb, and 10◦ of active extension in the metacarpophalangeal and interphalangeal joints of the other fingers Exclusion Criteria: * Patients with epilepsy or seizure disorder * Patients with history of botulinum toxin injection, cognitive impairment, fracture and any surgical procedure in upper extremity

Contact & Investigator

Central Contact

IMRAN AMJAD, PhD

✉ imran.amjad@riphah.edu.pk

📞 9233224390125

Principal Investigator

Maida Shabbir, MS-PT

PRINCIPAL INVESTIGATOR

Riphah International University

Frequently Asked Questions

Who can join the NCT07244042 clinical trial?

This trial is open to participants of all sexes, aged 5 Years or older, up to 13 Years, studying Pediatric Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07244042 currently recruiting?

Yes, NCT07244042 is actively recruiting participants. Contact the research team at imran.amjad@riphah.edu.pk for enrollment information.

Where is the NCT07244042 trial being conducted?

This trial is being conducted at Lahore, Pakistan.

Who is sponsoring the NCT07244042 clinical trial?

NCT07244042 is sponsored by Riphah International University. The principal investigator is Maida Shabbir, MS-PT at Riphah International University. The trial plans to enroll 20 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology